Bone Biologics (BBLG) CEO receives 16,668 stock options at $1.55 strike

Rhea-AI Filing Summary

Bone Biologics Corp reported an insider equity award for its Chief Executive Officer, Jeff Frelick. On January 8, 2026, he received an employee stock option grant covering 16,668 shares of common stock with an exercise price of $1.55 per share. The filing states that this option was granted under the company’s 2015 Equity Incentive Plan, is exempt under Rule 16b-3, and, except as otherwise provided in the award notice, vests and becomes exercisable immediately.

After this grant, Frelick directly holds 16,668 of these new options, along with previously held, fully vested options on 9,019 shares at an exercise price of $5.82 and options on 8 shares at an exercise price of $73,800. He also directly owns 360 shares of Bone Biologics common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Frelick Jeff

(Last) (First) (Middle)

C/O BONE BIOLOGICS CORP,

2 BURLINGTON WOODS DR.SUITE 100

(Street)

BURLINGTON, MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bone Biologics Corp [ BBLG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								360	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option	$1.55	01/08/2026		A		16,668		01/08/2026	01/08/2036	Common Stock	16,668(1)	$0	16,668	D
Employee Stock Option	$5.82							(2)	01/15/2027	Common Stock	9,019		9,019	D
Employee Stock Option	$73,800							(2)	05/26/2026	Common Stock	8		8	D

Explanation of Responses:

1. This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable immediately.

2. This option is fully vested as of the date of this report.

	/s/ Jeff Frelick	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Bone Biologics Corp (BBLG) report for its CEO?

Bone Biologics Corp reported that its Chief Executive Officer, Jeff Frelick, received an employee stock option grant on January 8, 2026, covering 16,668 shares of common stock at an exercise price of $1.55 per share.

How many Bone Biologics (BBLG) options were granted to the CEO and at what price?

Jeff Frelick was granted 16,668 employee stock options, each giving the right to buy one share of Bone Biologics common stock at an exercise price of $1.55 per share.

When do the new Bone Biologics (BBLG) stock options for the CEO vest and expire?

The filing states the newly granted option vests and becomes exercisable immediately, except as otherwise provided in the award notice, and has an expiration date of January 8, 2036.

What other Bone Biologics (BBLG) options does the CEO hold after this Form 4?

After the reported transactions, Jeff Frelick holds fully vested options on 9,019 shares with a $5.82 exercise price and options on 8 shares with a $73,800 exercise price, in addition to the new 16,668-share grant.

How many Bone Biologics (BBLG) common shares does the CEO own directly?

According to the Form 4, Jeff Frelick directly owns 360 shares of Bone Biologics common stock following the reported transactions.

Under which plan were the new Bone Biologics (BBLG) stock options granted to the CEO?

The new employee stock options for Jeff Frelick were granted under the Bone Biologics Corporation 2015 Equity Incentive Plan and are described as exempt under Rule 16b-3.